Phcog.Net logo
Submit

BROWSE ALL JOURNALS

    SEE ALL 1 JOURNALS
    Pharmacognosy ResearchNOW IN
    Review

    Siddha Medicine in Cardiovascular Care: Clinical Evidence and Pharmacological Perspectives for Integrative Management-An Integrative Review

    Nikil Niva John Raja1★, Hema Nandhini Devi Veluchamy2★ Corresponding author

    1. 1Department of Outpatient, Siddha Clinical Research Unit, Central Council for Research in Siddha, Ministry of Ayush, Government of India, Safdarjung Hospital, New Delhi, INDIA.
    2. 2Department of Pharmacovigilance, Siddha Clinical Research Unit, Central Council for Research in Siddha, Ministry of Ayush, Government of India, Safdarjung Hospital, New Delhi, INDIA.

    CORRESPONDENCE

    Nikil Niva John Raja

    Research Associate (Siddha)-III, Department of Outpatient, Siddha Clinical Research Unit, Central Council for Research in Siddha, Ministry of Ayush, Government of India, Safdarjung Hospital, New Delhi-110029, INDIA.

    nikilniva@gmail.com

    Received: 06-03-2026; Revised: 13-05-2026; Accepted: 14-07-2026.

    Volume 18, Issue 4 · pp. 1150–1158 · PUBLISHED Jul-Sep 2026 · DOI: 10.5530/pres.20260030

    ABSTRACT

    Cardiovascular Diseases (CVDs) are leading causes of mortality globally and in India, contributing substantially to the burden of noncommunicable diseases. The Siddha system of medicine recommends several internal formulations for cardiovascular care; however, the consolidation of scientific evidence supporting these therapies is necessary to strengthen their role in integrative healthcare. The objective was to compile and analyze available preclinical, toxicity, and clinical evidence on Siddha internal medicines recommended for the management of cardiovascular diseases. This descriptive evidence-based review included preclinical studies, acute and chronic toxicity studies, clinical trials (case reports, case series, pilot studies, and randomized controlled trials), and postgraduate and doctoral theses related to Siddha formulations indicated for CVD treatment. Molecular docking studies and literature reviews of individual ingredients were excluded. A comprehensive search was conducted in PubMed, Embase, Web of Science, Science Direct, the Cochrane Library, and Google Scholar via relevant keywords with Boolean operators. The data were compiled and analyzed systematically. Thirty-four Siddha internal formulations recommended for cardiovascular diseases were identified. Among these compounds, 17 demonstrated antioxidant activity, 8 exhibited anti-inflammatory effects, 2 exhibited cardioprotective properties, 2 exhibited antihypertensive activity, 4 exhibited hypolipidemic effects, and 1 exhibited antiatherogenic action. Several formulations have also shown antidiabetic, Hepatoprotective, and immunomodulatory activities relevant to CVD comorbidities. Toxicity studies conducted on selected formulations indicated acceptable safety profiles under experimental conditions. Limited clinical evidence suggests improvements in lipid parameters and cardiovascular health indicators. Siddha internal medicines exhibit pharmacological activities relevant to cardiovascular disease management. While preclinical evidence is substantial, robust, large-scale clinical trials are warranted to validate efficacy and ensure safe integration into evidence-based cardiovascular care.

    KEYWORDS

    0% READ

    FULL TEXT

    INTRODUCTION

    Noncommunicable Diseases (NCDs) pose considerable challenges to global health. These diseases significantly impact public health systems and require effective strategies for prevention and management (Sharma et al., 2024). NCDs, commonly referred to as chronic diseases, are characterized by a prolonged duration and result in a complex interplay of genetic, physiological, environmental, and behavioral factors. The primary categories of NCDs include cardiovascular diseases-such as heart attacks and strokes-various forms of cancer, chronic respiratory diseases (including chronic obstructive pulmonary disease and asthma), and diabetes. Notably, NCDs have a disproportionately severe impact on populations in low- and middle-income countries, where approximately three-quarters of global NCD-related fatalities, totaling 32 million, occur (Non communicable diseases, 2025). In 2023, NCDs continue to pose a significant global health challenge, accounting for 74% of total deaths and 86% of premature deaths from NCDs in Low- and Middle-Income Countries (LMICs) (Varghese et al., 2025).

    In India, NCDs are responsible for approximately 6 million deaths each year, accounting for approximately 63% of all annual fatalities (Krishnan et al., 2025). Between 1990 and 2023, the proportion of deaths attributable to NCDs in India substantially increased, increasing from 37.9% to 66%. In many developed nations, NCDs typically manifest in individuals aged 55 years or older; however, in India, the onset of these diseases tends to occur approximately a decade earlier. The growing prevalence of NCDs in India is further aggravated by the increasing incidence of multimorbidity, particularly among adults residing in urban areas. Given the chronic nature of these illnesses, individuals frequently endure disabilities or diminished quality of life for prolonged periods, resulting in continuous emotional and financial strain (Hemram et al., 2025).

    In response to the increasing incidence of NCDs, India established the National Programme for the Prevention and Control of Cancer, Diabetes, Cardiovascular Disease, and Stroke (NPCDCS) in 2010. This program positioned India as the inaugural country to implement the global NCD monitoring framework and to set national objectives aimed at reducing premature mortality associated with these diseases (MoHFW, 2017). Despite significant advancements in public health, including lower mortality rates and longer life expectancies, India still faces considerable challenges in addressing NCDs (Chaurasia, 2017; Singh et al., 2017).

    Ayush systems possess considerable potential to significantly contribute to the prevention and management of NCDs such as diabetes, cardiovascular disease, cancer, and stroke. The 12th Five-Year Plan for health in India advocates the integration of Ayush systems, particularly in their areas of expertise, which encompass preventive and promotive health care, as well as the treatment of health conditions affecting women, children, elderly individuals, NCDs, mental health disorders, palliative care, and rehabilitation. The National Programme for Prevention and Control of Cancers, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS), established by the Indian Government, has incorporated Ayush interventions to address the escalating burden of NCDs and associated risk factors at designated pilot sites. This initiative serves as a commendable model for further integration efforts. The implementation of early screening, accurate identification, and timely referrals within these integrated programs, coupled with the promotion and adoption of Ayush-based lifestyle practices, can significantly increase efforts to prevent and manage NCDs (Kumar et al., 2023).

    As the incidence of morbidity and mortality related to NCDs continues to escalate annually, it is imperative to adopt a preventive strategy grounded in the Siddha system of medicine. This ancient and holistic approach underscores the importance of maintaining a balanced lifestyle and adhering to established health guidelines. By strictly following the lifestyle prescriptions advocated within the Siddha framework-such as nutritional recommendations, physical activity regimens, and mental well-being practices-individuals can substantially decrease their risk of developing NCDs. These preventive measures can not only effectively manage the onset of these debilitating diseases but also contribute to their prevention, thereby increasing overall health and longevity (Lekha et al., 2015).

    In Siddha medicine, various botanical species and their formulations have been demonstrated to offer significant benefits in the management of cardiovascular conditions. The marudham pattai (Terminalia arjuna) tree and its constituents, particularly arjunolic acid, exhibit a cardioprotective effect in rats, which is attributable to their antioxidant properties (Singh et al., 2024). In the Siddha system of medicine, herbs, minerals, and therapeutic techniques are utilized to treat respiratory diseases, such as wheezing, coughing, and shortness of breath (Panneerselvam et al., 2025). Many medicines are recommended for respiratory diseases, such as Thalisathi chooranam, Adathodai manapagu, Thirikadugu chooranam, and Thoothuvalai Nei (Shalini et al., 2025). Many Siddha medicines are recommended for the integrative management of Noncommunicable Diseases (NCDs).

    The "Standard Treatment Guidelines on Management of Metabolic Disorders in the Siddha System of Medicine," published by the Ayush Vertical of the Directorate General of Health Services in New Delhi in April 2025 (STG, 2025), along with the Siddha Standard Treatment Guidelines released by the National Institute of Siddha (STG 2019), detail a range of internal and external medications for the four primary NCDs: cardiovascular diseases, cancer, chronic respiratory diseases (including chronic obstructive pulmonary disease and asthma), and diabetes.

    A significant number of these medications contain phytoconstituents, and numerous clinical studies have demonstrated their pharmacological efficacy in the management and treatment of Noncommunicable Diseases (NCDs). The scientific validity and safety considerations of Siddha medicines are crucial in the integrated approach to addressing NCDs.

    The primary aim of this comprehensive review is to collect and analyze data that support the scientific validity of internal medicines for Cardiovascular Diseases (CVDs), as outlined in the aforementioned guidelines for the integrative treatment of Noncommunicable Diseases (NCDs). Furthermore, the secondary objective of this review is to investigate strategies to enhance the scientific framework associated with the improvement of the aforementioned pharmaceutical interventions.

    METHODOLOGY

    Study Selection

    This descriptive review encompasses preclinical studies, acute and chronic toxicity studies, and clinical trials, including case studies, case reports, case series, pilot studies, Randomized Controlled Trials (RCTs) and doctoral and postgraduate theses. This review specifically excludes molecular docking studies and literature reviews concerning the individual ingredients of the medicines.

    Search strategy

    The present study involved an extensive search of various search engines and biomedical databases, such as PubMed, Embase, Web of Science, Science Direct, Cochrane Reviews, and Google Scholar, using keywords such as Siddha, traditional medicine, ancient wisdom, NCDs, CVD, pharmacological actions, toxicity, etc., and Boolean operators, such as AND, OR, NOT, AND NOT.

    Data collection

    To establish a correlation between Siddha disease terminologies and their English counterparts, the World Health Organization's publication on International Standard Terminologies in Siddha Medicine was utilized.

    Data compilation, processing, and statistical analyses were conducted systematically, employing basic statistical methods in Microsoft Excel 2010. The information obtained from the comprehensive literature review has been tabulated, analyzed, and reported in this manuscript.

    RESULTS

    According to the Standard Treatment Guidelines for the Management of Metabolic Disorders within the Siddha System of Medicine, 34 medicinal formulations are listed under the section dedicated to cardiovascular diseases. This compilation includes 6 Kudineer (decoction), 10 Chooranam (medicinal powders), 2 Rasayanam (semi-solid confection), 1 Ilagam (electuary), 4 Mathirai (pills/tablets), 9 Parpam (white calx), and 2 Chendooram (red calx). Among these 34 formulations, 17 demonstrate antioxidant activity, 8 possess anti-inflammatory properties, 1 has antiatherogenic effects, 2 are identified as cardioprotective, 2 possess antihypertensive properties, and 4 exhibit hypolipidemic activities. The pharmacological actions of each medicine are outlined in Table 1, and the significant activities related to CVDs in Siddha medicines are shown in Table 2.

    Table 1: Siddha Internal Medicines for Cardiovascular Diseases: Preclinical, Pharmacological, Toxicity, and Clinical Evidence.
    Sl. No.Name of the internal medicinePreclinical StudiesPharmacological actionsToxicity studyClinical studies related to CVDs
    Cardiovascular Diseases (CVDs)
    1Venthamarai kudineer----
    2Thamaraga kudineer----
    3Maruthampattai kudineer(Vinubharathi et al., 2019 and Vinubharathi et al., 2018).Antioxidant (Vinubharathi et al., 2019), antidiabetic (Vinubharathi et al., 2018).(Vinubharathi et al., 2019)-
    4Nerunjil kudineer(Praba et al., 2018 and Akila et al., 2013 and Alam et al., 2019).Antiurolithiasis (Praba et al., 2018), anti-inflammatory, antinociceptive (Akila et al., 2013), Nephroprotective (Alam et al., 2019).(Noorul Alam, 2019 and Akila et al., 2012)-
    5Adathodai kudineer(Perumal et al., 2020).Antioxidant, anti-atherogenic (Perumal et al., 2020).--
    6Thiratchai kudineer(Mantela et al., 2024).Hepatoprotective, antioxidant (Mantela et al., 2024).(Mantela et al., 2024)-
    7Amukkara chooranam(Jain et al., 2018 and Rajamohamed et al., 2019 and Punitha, 2013 and Patra et al., 2014).Immunomodulatory, antioxidant (Jain et al., 2018), antibiofilm (Rajamohamed et al., 2019), hypolipidemic (Punitha, 2013), antiulcer (Patra et al., 2014).(Jain et al., 2018 and Patra et al., 2014)(Punitha et al., 2018)
    8Dhratchathy chooranam(Ganapathy et al., 2020).Cardio protective, antioxidant, anti-inflammatory (Ganapathy et al., 2020).(Ganapathy et al., 2020)-
    9Elathy chooranam(Tamilselvan et al., 2022 and Rajalakshmi et al., 2017).Antihypertensive (Tamilselvan et al., 2022), antioxidant, anti-inflammatory (Rajalakshmi et al., 2017).--
    10Venthamarai chooranam(Babu et al., 2014; Ravichandran, 2014 and Indrakumar, 2016).Antihypertensive (Babu et al., 2014), cardio protective (Ravichandran, 2014), Thrombolytic, Vasodilator, Hypolipidemic, Cardio protective (Indrakumar, 2016)(Babu et al., 2014)-
    11Seenthil chooranam(Sheeba et al., 2025; Sivamanisha et al., 2022).Antidiabetic, Hepatoprotective, antimicrobial, antihistamine, antioxidant, anti-obesity, anti-asthmatic (Sheeba et al., 2025), immunomodulatory (Sivamanisha et al., 2022).(Sheeba et al., 2025)-
    12Keezhanelli chooranam(Kumar et al., 2023 and Chinraji et al., 2025 and Nikil Niva et al., 2025).Hematinic (Kumar et al., 2023), Hepatoprotective, hypolipidemic (Chinraji et al., 2025), antioxidant, anti-inflammatory, antiviral (Nikil Niva et al., 2025).(Kumar et al., 2023)-
    13Panchadeepakini chooranam(Rakshitaa et al., 2015).Antioxidant, antimicrobial (Rakshitaa et al., 2015).--
    14Maruthampattai chooranam(Manoharan et al., 2023).Hypolipidemic (Manoharan et al., 2023).--
    15Karpoorathi chooranam----
    16Asai chooranam(Keerthana et al., 2018).Antioxidant (Keerthana et al., 2018).--
    17Inji Rasayanam(Ashok Kumar et al., 2014).Antiurolithiatic (Ashok Kumar et al., 2014).--
    18Parangi Rasayanam(Mahalakshmi et al., 2021 and Kaaruniya et al., 2020 and Kavita Chandra, 2023 and Mahalakshmi et al., 2024).Antioxidant (Mahalakshmi et al., 20210, anticancer (Kaaruniya et al., 2020), antifungal (Kavita Chandra, 2023), anti- psoriatic (Mahalakshmi et al., 2024).(Non Communicable Diseases, 2025; Alam, 2019)-
    19Kesari ilagam----
    20Kasthuri maathirai(Vanitha et al., 2020).Antioxidant (Vanitha et al., 2020).--
    21Korosanai maathirai(Tamil Muhil et al., 2018).Antimicrobial (Tamil Muhil et al., 2018).--
    22Vasantha kusumakara maathirai(Indhumathi et al., 2023 and Indhumathi et al., 2018).Anti- histamine (Indhumathi et al., 2023), Bronchodilator (Indhumathi et al., 2018).(Indhumathi et al., 2022)-
    23Poorana chandhirodaya maathirai(Hazeena Begum et al., 2014 and Muthukumaran Pakkirisamy et al., 2022 and Vaishnavi et al., 2024 and Balasubramanian et al., 2024).Antioxidant (Hazeena Begum et al., 2014 and Muthukumaran Pakkirisamy et al., 2022), anticancer (Vaishnavi et al., 2024), anti-amnesic (Balasubramanian et al., 2024).(Muthukumaran et al., 2020)-
    24Silasathu parpam(Thirupathi et al., 2002).Antiulcer (Thirupathi et al., 2002), spermatogenic (Balasubramaniyan et al., 2014), Antihyperglycemic (Revathy, 2019), Diuretic, Lithotriptic (Nikil Niva et al., 2024), anti-inflammatory, antinociceptive (Christian CBS et al., 2024).(Vikesh et al., 2018)-
    25Sangu parpam(Thirupathi et al., 2002).Antiulcer (Thirupathi et al., 2002), anti-inflammatory, antioxidant (Nikil Niva et al., 2026).(Madhavan et al., 2021)-
    26Muthuchippi parpam(Ganesan et al., 2016).Antioxidant, antimicrobial (Ganesan et al., 2016), antiulcer, anti-inflammatory, Anti osteoporotic (Senthil Velu Kanthal et al., 2017).--
    27Aya naaga parpam----
    28Muthu parpam(Chitra et al., 2023).Antioxidant (Chitra et al., 2023), anticataract (Chitra et al., 2024), neuroprotective (Sabari girija et al., 2020), anti-inflammatory (Shanmugapriya et al., 2025).(Jenifer Vimala et al., 2022)
    29Sirungi parpam(Omprakash et al., 2011).Antiulcer (Omprakash et al., 2011).(Omprakash et al., 2011)
    30Pavala parpam(Thanuja et al., 2021).Hemostatic, Hepatoprotective (Thanuja et al., 2021), antibacterial (Thanigavelan et al., 2011).(Thanuja et al., 2021)
    31Kaariya parpam----
    32Uppu parpam(Kavitha et al., 2013).Folliculogenitic (Kavitha et al., 2013).--
    33Kalameganarayana chendooram(Satheesh et al., 2024).Anticancer (Satheesh et al., 2024).(Ramkumar et al., 20140
    34Ekku chendooram----
    Table 2: Pharmacological Activities of Siddha Formulations Used in Cardiovascular Diseases.
    Formulation Type (Total)AntioxidantCardioprotectiveAntihypertensiveHypolipidemicAnti-atherogenicAnti-inflammatory
    Kudineer (6)311001
    Chooranam (10)811413
    Rasayanam (2)100001
    Ilagam (1)000000
    Mathirai (4)200000
    Parpam (9)300004
    Chendooram (2)000000

    DISCUSSION

    Cardiovascular Diseases (CVDs) remain a leading cause of morbidity and mortality globally and in India, where they account for a significant proportion of Noncommunicable Disease (NCD)-related deaths (Krishnan et al., 2025). The present review consolidates scientific evidence on the pharmacological efficacy of Siddha internal medicines recommended for CVD management, highlighting their potential role in integrated healthcare approaches.

    The 34 Siddha formulations identified for cardiovascular diseases have diverse pharmacological effects, including antioxidant, anti-inflammatory, cardioprotective, antihypertensive, antiatherogenic, and hypolipidemic effects. The antioxidant activity of 17 formulations plays a central role in CVD prevention and management by mitigating oxidative stress, which is a well-established contributor to endothelial dysfunction, atherosclerosis, and myocardial injury (Vinubharathi et al., 2019; Keerthana et al., 2018; Hazeena Begum et al., 2014). The anti-inflammatory properties of 8 formulations further reduce vascular inflammation, which underlies plaque formation and the progression of coronary artery disease (Ganapathy et al., 2020; Rajalakshmi, et al., 2017; Nikil Niva et al., 2026).

    The cardio protective activity of formulations such as Dhratchathy Chooranam and Venthamarai Chooranam likely arises from the synergistic effects of phytochemicals, including flavonoids, saponins, and polyphenols. These compounds modulate lipid metabolism, reduce oxidative damage, and stabilize myocardial cellular function, as evidenced in preclinical studies (Kumar et al., 2023; Mahalakshmi et al., 2021; Mahalakshmi et al., 2016. The antihypertensive and hypolipidemic properties of certain formulations complement conventional pharmacotherapy by regulating blood pressure and lipid profiles, which are critical risk factors for CVD morbidity and mortality (Tamilselvan et al., 2022; Babu et al., 2014; Indrakumar, 2016; Kumar et al., 2023; Manoharan et al., 2023).

    Preclinical studies indicate robust pharmacological actions across multiple Siddha formulations, including antidiabetic, hepatoprotective, immunomodulatory, and antiulcer activities, which are relevant in the context of CVD comorbidities (Vinubharathi et al., 2018; Jain et al., 2018; Rajamohamed et al., 2019; Punitha, 2013; Patra et al., 2014; Sheeba et al., 2025). Toxicity studies performed on several formulations, such as Amukkara Chooranam, Keezhanelli Chooranam, and Silasathu Parpam, have demonstrated safety profiles that support their clinical use (Jain et al., 2018; Patra et al., 2014; Kumar et al., 2023; Vikesh et al., 2018).

    Clinical evidence, although limited in scope, supports the efficacy of these formulations in human subjects. Studies on Amukkara Chooranam, Parangi Rasayanam, and Maruthampattai Kudineer have revealed improvements in lipid profiles, glycemic control, and overall cardiovascular health (Vinubharathi et al., 2019; Punitha et al., 2018; Muthukumaran et al., 2020). These findings align with the pharmacological rationale observed in preclinical models, suggesting translational potential for the integrative management of CVDs.

    The multifactorial actions of Siddha medicines can be attributed to their polyherbal and mineral compositions, which act through complementary pathways: antioxidant activity neutralizes reactive oxygen species, protecting endothelial and myocardial cells (Baharuddin, 2024). Anti-inflammatory mechanisms inhibit proinflammatory cytokines (e.g., TNF-α and IL-6) and reduce vascular inflammation (Popko et al., 2010). Lipid-lowering and hypolipidemic effects prevent atherogenesis and improve blood lipid profiles (Majdalawieh et al., 2023). Cardioprotective and antihypertensive actions enhance myocardial resilience and reduce cardiac workload (Nagata et al., 2011). Such multifaceted pharmacodynamics offer advantages over single-target conventional drugs, particularly in managing complex conditions such as CVDs, which involve intertwined metabolic, inflammatory, and oxidative pathways (Kabir et al., 2022).

    The integration of Siddha formulations into mainstream cardiovascular care aligns with national health initiatives, including the NPCDCS, and supports preventive strategies. The incorporation of lifestyle modifications, early screening, and Siddha-based therapeutics can help delay disease onset, reduce complications, and enhance quality of life, particularly in populations prone to premature CVD onset, such as urban adults in India (Kumar et al., 2023; Lekha et al., 2015).

    LIMITATIONS AND FUTURE DIRECTIONS

    While preclinical evidence is extensive, clinical studies on Siddha cardiovascular medicines remain limited in scale, sample size, and methodological rigor. Standardized clinical trials with larger cohorts and long-term follow-up are necessary to validate the efficacy and safety of these methods. Additionally, mechanistic studies at the molecular and genomic levels could further elucidate the pathways modulated by these formulations, enhancing their scientific credibility.

    Future research should also explore drug–herb interactions, dose optimization, and pharmacokinetics, ensuring safe integration with conventional therapies. Strengthening pharmacovigilance and quality control measures for Siddha formulations will be crucial for broader clinical adoption.

    CONCLUSION

    This review demonstrates that Siddha internal medicines exhibit significant pharmacological activities relevant to the management of cardiovascular diseases, including antioxidant, anti-inflammatory, cardioprotective, antihypertensive, and hypolipidemic effects. Preclinical and limited clinical evidence supports their efficacy and safety, highlighting their potential role in integrative strategies for CVD prevention and management. Comprehensive clinical studies and mechanistic research are warranted to consolidate these findings and facilitate evidence-based incorporation of Siddha therapies into mainstream cardiovascular care.

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

    1. Akila, B, & Manickavasakam, K. (2012). Oral acute and sub acute toxicity studies of two siddha formulations vedikara silasathu parpam (VSP) and nerunjil kudineer (NK) in experimental rats. Int J Pharm Pharm Sci, 4(2), 88–90.GOOGLE SCHOLAR
    2. Akila, B, & Manickavasakam, K. (2013). Anti-inflammatory and antinociceptive activity of two siddha formulations in combination. Int J Pharm Sci Res, 4(2), 856–861. https://doi.org/10.13040/IJPSR.0975-8232.4(2DOIGOOGLE SCHOLAR
    3. Alam, N, Gopal, V, Vasanthi, C, & Manna, P. (2019). K. Nephroprotective Potential of Neermulli/nerunjil Kudineer on Cisplatin Induced Nephrotoxicity in Wistar Albino Rats. Int J Res Pharm Sci, 10(3), 1720–1729. https://doi.org/10.26452/ijrps.v10i3.1362DOIGOOGLE SCHOLAR
    4. Babu, C. (2014). S; Kalaivani, P; Ranju, V; Sathiya, S; Anbarasi, C; Mahadevan, M. V. et Al. Venthamarai Chooranam, a Polyherbal Siddha Medicine, Alleviates Hypertension Via AT₁R and eNOS Signaling Pathway in 2k1c Hypertensive Rats. Experimental Biology and Medicine (maywood, N.j.), 239(6), 758–769. https://doi.org/10.1177/1535370214525317DOIGOOGLE SCHOLAR
    5. Baharuddin, B. (2024). Antioxidant protection mechanisms in the cardiovascular system. Asian Journal of Medicine and Health, 22(6), 140–146. https://doi.org/10.9734/ajmah/2024/v22i61029DOIGOOGLE SCHOLAR
    6. Balasubramanian, C, & Ramaswamy, R. (2024). S. Evaluation of Nootropic and Neuroprotective Properties of Siddha Drug Poorana Chandrothaya Chenthuram (PCC) in Scopolamine-induced Amnesia in Mice. Phytomedicine Plus, 4(3), 100585. https://doi.org/10.1016/j.phyplu.2024.100585DOIGOOGLE SCHOLAR
    7. Balasubramaniyan, A, Manickavasakam, K, & Shakila, R. (2014). Chemical analysis of gomutra silasathu parpam. International Journal of Drug Delivery, 6(1), 88.GOOGLE SCHOLAR
    8. Begum, H, V, & Muthukumaran, P. (2014). Phytochemical and free radical scavenging activity of poorna chandrodayam chendooram (metallic herbal based drug). The Journal of Phytopharmacology, 3(6), 418–422. https://doi.org/10.31254/phyto.2014.3608DOIGOOGLE SCHOLAR
    9. Chandra, & Kavita (2023). In vitro screening of parangi Rasayanam, A siddha Drug, for its antifungal property. EIJMRMS, 3(6), 1–4. https://doi.org/10.55640/eijmrms-03-06-01DOIGOOGLE SCHOLAR
    10. Chaurasia, A. (1950). R. Fertility, Mortality and Age Composition Effects of Population Transition in China and India: -2015. Comparative Population Studies, 2017, 42. https://doi.org/10.12765/cpos-2017-12DOIGOOGLE SCHOLAR
    11. Chinraji, E, Varatharaju, E, Rengaraju, M, & Muthiah, K. (2025). Management of hepatitis B with siddha Medicine: A case report. Journal of Clinical and Diagnostic Research, 19(2). https://doi.org/10.7860/JCDR/2025/74188/20674DOIGOOGLE SCHOLAR
    12. Chitra, V, Kehren, R, Rayma, Mahalakshmi, V, Muthukumar, N. J, & Akila, M. (2024). Et al. Evaluation of Anti-cataract Activity of the Siddha Formulation Muthu Parpam Using Isolated Goat Lens Model. Journal of Advanced Zoology, 45(2), 744–746. https://doi.org/10.53555/jaz.v45i2.3992DOIGOOGLE SCHOLAR
    13. Chitra, V, Sankaran, V, Mahalakshmi, V, Sugasini, P, Samundeshwari, P, Muthukumar, N, & J (2023). Et al. In Vitro Antioxidant Activity of Siddha Herbomineral Formulation Muthu Parpam. Journal of Chemical Health Risks, 13(6), 458–465.GOOGLE SCHOLAR
    14. Christian, C. B. S, B, Devi, P, N, Shiny, S, E, J, & J (2024). A siddha management of attai vidal with internal and external medicines for naalavibatha punn (varicose Ulcer): A case report. International Journal of Ayurvedic Medicine, 15(2), 590–600. https://doi.org/10.47552/ijam.v15i2.4569DOIGOOGLE SCHOLAR
    15. Diseases, N. C. (2025). World health organization.GOOGLE SCHOLAR
    16. Ganapathy, R, Ramachandran, A, & Shivalingaiah, S. (2020). B; Bishir, M; Bhojaraj, S; Sridhar, S. Et Al. Cardioprotective Potential of Polyphenols Rich Thraatchathi Chooranam Against Isoproterenol Induced Myocardial Necrosis in Experimental Rats. BMC Complementary Medicine and Therapies, 20(1), 356. https://doi.org/10.1186/s12906-020-03124-xDOIGOOGLE SCHOLAR
    17. Ganesan, R, Raj, P, R, Priya, R, R, & Elankani, P. (2016). Evaluation of antioxidant and antimicrobial activities of muthuchippi parpam - A siddha drug. Asian Journal of Research in Biological and Pharmaceutical Sciences, 4(1), 21–25.GOOGLE SCHOLAR
    18. girija, S, N, S, G, M. A, S, L, S, P, & S (2020). In vitro screening for acetylcholinesterase enzyme inhibition potential of muthu parpam - Therapeutic lead for Alzheimer’s disease. Asian Journal of Pharmaceutical and Clinical Research, 13(8), 56–58. https://doi.org/10.22159/ajpcr.2020.v13i8.38062DOIGOOGLE SCHOLAR
    19. Hemram, A, Chettri, D, & Subba, D. (2017). Rural-urban differentials in prevalence of non-communicable diseases (NCDs) and its contextual determinants in India: A secondary data analysis of the 75th round of NSSO (2017-18). Discover Public Health, 2025, 22. (1):680. https://doi.org/10.1186/s12982-025-01087-3DOIGOOGLE SCHOLAR
    20. Indhumathi, M, & Shanuvas, A. (2023). Potency of vasanthakusumakara mathirai for Anti- Histamine activity by vascular permeability model in rats. IOSR Journal of Research and Method in Education, 12(1), 14–16. https://doi.org/10.9790/7388-1201011416DOIGOOGLE SCHOLAR
    21. Indhumathi, M, Shanuvas, A, & Velpandian, V. (2018). Evaluation of bronchodilator activity of siddha herbo mineral drug “vasanthakusumakara mathirai” by exposing guinea pig in histamine aerosol. Journal of Medical Science and Clinical Research, 6(6), 371–374. https://doi.org/10.18535/jmscr/v6i6.63DOIGOOGLE SCHOLAR
    22. Indhumathi, M, S.Karthi, & A.Shanuvas (2022). Toxicity studies of a herbomineral formulation vasanthakusumakara mathirai in rats. Int. J. Curr. Res. Med. Sci, 8(10), 38–46. https://doi.org/10.22192/ijcrms.2022.08.10.006DOIGOOGLE SCHOLAR
    23. Indrakumar, J. (2016). Preclinical study of siddha drug venthamaraiyathi chooranam for it’s Thrombolytic, Vasodilator, hypolipidemic and cardio protective activities. Chennai.: the Tamil Nadu DR. MGR Medical University.GOOGLE SCHOLAR
    24. Jain, J, Narayanan, V, Chaturvedi, S, Pai, S, & Sunil, S. (2018). In vivo evaluation of withania somnifera-based indian traditional formulation (amukkara choornam), against chikungunya virus-induced morbidity and arthralgia. Journal of Evidence-based Integrative Medicine. 23:2156587218757661. https://doi.org/10.1177/2156587218757661DOIGOOGLE SCHOLAR
    25. Kaaruniya, G, Sivakkumar, S, Visweswaran, S, Mariappan, A, Kumari, M, & R (2020). Anticancer potential of siddha herbo mineral formulation parangi rasayanam against HeLa cell lines: A in vitro study. International Journal of Botany Studies, 5(6), 157–160.GOOGLE SCHOLAR
    26. Kabir, A, & Muth, A. (2022). Polypharmacology: The science of multi-targeting molecules. Pharmacological Research, 176, 106055. https://doi.org/10.1016/j.phrs.2021.106055DOIGOOGLE SCHOLAR
    27. Kanthal, Velu, S, Chitra, V, Rahul, V. A, Usha, S, Gladys, J, & R (2017). Scientific evaluation of siddha formulation muthuchippi Parpam-A review. International Journal of Ayurveda and Pharma Research, 5(1).GOOGLE SCHOLAR
    28. Kavitha, N, Velpandian, V, Kumar, A, Ayyasamy, S, Kumar, P, M, & Banumath, V. (2013). Ovulation inducing and folliculogenetic activity of uppu parpamin female wistar albino rats. Pharmanest - an International Journal of Advances in Pharmaceutical Sciences, 4(2).GOOGLE SCHOLAR
    29. Keerthana, R, Sivakkumar, S, Visweswaran, S, Maariappan, A, & Banumathi, V. (2018). Evaluation of antioxidant activity of seeraga chooranam in vitro assay (a siddha polyherbal preparation). Int J Ayu Pharm Res, 6(7).GOOGLE SCHOLAR
    30. Krishnan, N, Green, H, Lee, J, Flood, D, Singh, K, & Sekher, T. (2025). V. Et Al. Prevalence of Non-communicable Disease Risk Factors and Chronic Conditions Among Middle-aged and Older Adults in Extreme Poverty: a Nationally Representative Cross-sectional Study in India. the Lancet. Global Health, 13(11), e1955. –e1963. https://doi.org/10.1016/S2214-109X(25DOIGOOGLE SCHOLAR
    31. Kumar, A. (2023). R; Gunalan, G; Firdouse, K. H. H; Archana, A. Pre-clinical Studies of Siddha Formulations Advocated for Anaemia: a Systematic Review and Meta-analysis. Journal of Applied Pharmaceutical Science, 13(8), 185–203. https://doi.org/10.7324/JAPS.2023.126389DOIGOOGLE SCHOLAR
    32. Kumar, A, B, S, Krishna, V, N, Ragavendhra, B, S, Saran, & Gopisetty (2014). Antiurolithiatic activity of inji Rasayanam, A siddha formulation. Asian Journal of Pharmaceutical Technology and Innovation, 2(7), 87–90.GOOGLE SCHOLAR
    33. Kumar, S, & Gopal, K. (2023). M; Choudhary, A; Soman, A; Namburi, U. R. S. Advancing the One Health Approach Through Integration of Ayush Systems: Opportunities and Way Forward. Journal of Family Medicine and Primary Care, 12(9), 1764–1770. https://doi.org/10.4103/jfmpc.jfmpc_192_23DOIGOOGLE SCHOLAR
    34. Lekha, G. (2015). S; Sathiyarajeswaran, P. Management of Non Communicable Diseases By Siddha System. an International Journal of Research in AYUSH and Allied Systems, 2(4), 251–258.GOOGLE SCHOLAR
    35. Madhavan, R, Adithya, S, Giridharan, B, Murugesan, M, & Raja, R. (2021). L. Acute and Sub Acute Toxicity Study on Sangu Parpam. Bioinformation, 17(1), 46–52. https://doi.org/10.6026/97320630017046DOIGOOGLE SCHOLAR
    36. Mahalakshmi, V, & Hazel, A. (2021). M; Muthukumar, N. J; Meenakumari, R. in Vitro Antioxidant Activity of Parangipattai Rasayanam (PRM)-A Siddha Polyherbal Formulation. Journal of Pharmaceutical Research International, 33(64B), 704–711. https://doi.org/10.9734/jpri/2021/v33i64B36235DOIGOOGLE SCHOLAR
    37. Mahalakshmi, V, & Ramaswamy, R. (2016). S; Muthukumar, N.J; Banumathy, V. Acute and Subacute (28-days) Oral Toxicity Studies of Parangipattai Rasayanam. Int. J. Curr. Res. Med. Sci, 2(5), 35–41.GOOGLE SCHOLAR
    38. Mahalakshmi, V, Hazel, A, A.M, Muthukumar, N. J, & Samundeeswari, P. (2024). Evaluation of Anti-Psoriatic activity of siddha formulation parangipattai rasayanam in HaCaT cell line using MTT assay. Intern. J. Zool. Invest, 10, 21–27. https://doi.org/10.33745/ijzi.2024.v10ispl1.003DOIGOOGLE SCHOLAR
    39. Majdalawieh, A. (2023). F; Eltayeb, A. E; Abu-yousef, I. A; Yousef, S. M. Hypolipidemic and Anti-atherogenic Effects of Sesamol and Possible Mechanisms of Action: a Comprehensive Review. Molecules (basel, Switzerland), 28(8), 3567. https://doi.org/10.3390/molecules28083567DOIGOOGLE SCHOLAR
    40. Manoharan, A, Manjula, M, Mubarak, H, & Babu, C. (2023). C. Hypolipidemic Activity of the Siddha Medicinal Plants. Int J Pharmacognosy, 2(4), 145–54. https://doi.org/10.13040/IJPSR.0975-8232.IJP.2(4DOIGOOGLE SCHOLAR
    41. Mantela, D, Sunilson, A. J, & J (2024). Exploring the hepatoprotective and antioxidant efficacy of the siddha polyherbal formulation thiratchai kudineer in Alcohol-Induced liver Injury: A preclinical evaluation. African Journal of Biomedical Research, 27(4S), 8102–8115. https://doi.org/10.53555/AJBR.v27i4S.5153DOIGOOGLE SCHOLAR
    42. Muhil, T, M, K, & Ramani, M. (2018). In vitro antimicrobial activity of siddha drug korosanai maathirai. International Journal of Research in Pharmaceutical and Nano Sciences, 7(3), 104–107.GOOGLE SCHOLAR
    43. Muthukumaran, P, & Begum, V. (2020). H. Effect of Poorna Chandrodayam Chendooram (PCM-metallic Drug) on Lipid Profile, Liver Function and Kidney Function Parameters of Rats. Asian J Pharm Anal, 10, 27–31. https://doi.org/10.5958/2231-5675.2020.00006.XDOIGOOGLE SCHOLAR
    44. Nagata, K, & Hattori, T. (2011). Cardioprotective mechanisms of lifestyle modifications and pharmacotherapies on cardiac remodeling and dysfunction in hypertensive heart disease: An overview. Nagoya Journal of Medical Science, 73(3-4), 91–105.GOOGLE SCHOLAR
    45. Niva, N, J, V, & H (2025). N. D; L, S; R, S; N J, M. Management of Hyperlipidaemia Using KNEA: a Case Report. Bioinformation, 21(8), 2697–2703. https://doi.org/10.6026/973206300212697DOIGOOGLE SCHOLAR
    46. Noorul, L. (2019). Effect of nanoformulation of nerunjil kudineer on cisplatin induced nephrotoxicity in animal model. Sri Ramachandra Institute of Higher Education and Research.GOOGLE SCHOLAR
    47. Omprakash, D, K, O. K, & R, R. (2011). Evaluation of antiulcer activity of maankombu parpam (sirungi bhasma). International Journal of Ayurvedic Medicine, 2(1). https://doi.org/10.47552/ijam.v2i1.42DOIGOOGLE SCHOLAR
    48. Pakkirisamy, Muthukumaran, Pattabiraman, K, Mohaideen, Vava, Begum, & Hazeena (2022). Adaptogenic potential of poorna chandrodayam chendooram (PCM-Metallic drug) on free radical and antioxidants levels in brain, liver and kidney of rats. Int J Chem Stud, 10(1), 163–169.GOOGLE SCHOLAR
    49. Panneerselvam, S, G, T, & AM, A. (2025). H; M, M. S. Anti-asthmatic Activity of Siddha Polyherbal Formulation Thoothuvalai Nei. International Journal of Ayurvedic Medicine, 15(4), 951–954. https://doi.org/10.47552/ijam.v15i4.5142DOIGOOGLE SCHOLAR
    50. Patra, K. (2014). C; jayaram Kumar, K; Ahirwar, D. K. Gastroprotective Effect of Standardized Extract of Amukkara Choornam on Experimental Gastric Ulcer in Rats. Journal of Natural Medicines, 68(2), 284–294. https://doi.org/10.1007/s11418-013-0792-xDOIGOOGLE SCHOLAR
    51. Perumal, R, vellingiri, V, sridharan, S, & Pemaiah, B. (2020). Evaluation of in vitro antioxidant and anti-atherogenic properties of selected siddha polyherbal decoctions. International Journal of Research in Pharmaceutical Sciences, 11(2), 1707–1715. https://doi.org/10.26452/ijrps.v11i2.2072DOIGOOGLE SCHOLAR
    52. Popko, K, Gorska, E, Stelmaszczyk-Emmel, A, Plywaczewski, R, Stoklosa, A, & Gorecka, D. (2010). Et al. Proinflammatory Cytokines Il-6 and TNF-α and the Development of Inflammation in Obese Subjects. European Journal of Medical Research. 15 Suppl, 2(Suppl 2), 120–122. https://doi.org/10.1186/2047-783x-15-s2-120DOIGOOGLE SCHOLAR
    53. Praba, T, Kingsly, A, Essakkypandian, G, Duraichi, A, & R (2018). Evaluation of in vitro anti-urolithiasis activity of nerunjil kudineer. Int. J. Curr. Res. Biol. Med, 3(5), 93–99. https://doi.org/10.22192/ijcrbm.2018.03.05.020DOIGOOGLE SCHOLAR
    54. prevention, N, M. A. P. F, & diseases, C. O. C. N. (2017). Ministry of health and family welfare (MoHFW). Government of India.GOOGLE SCHOLAR
    55. Punitha, A. (2013). Preclinical and clinical study on amukkara kizhangu chooranam for hypolipidemic activity in the management of athimetham (hyperlipidemia) and preclinical and clinical study on sarva noi linga chenduram for lithontriptic activity in the management of kalladaippu (renal calculi). National Institute of Siddha.GOOGLE SCHOLAR
    56. Punitha, A, Visweswaran, S, Muthukumar, N. J, & Banumathi, V. (2018). Pilot study of amukkara kizhangu chooranam in the management of hyperlipidemia (athimetham). Int. J. Adv. Multidiscip. Res, 5(2), 20–24. https://doi.org/10.22192/ijamr.2018.05.02.00DOIGOOGLE SCHOLAR
    57. Raja, John, N. N, Sridevi, L, Devi, H. N, & V (2026). Successful management of charcot foot ulcer through selected siddha Regimen-A case report. Research Journal of Pharmacy and Technology, 19(1), 250–6. https://doi.org/10.52711/0974-360X.2026.00035DOIGOOGLE SCHOLAR
    58. Raja, John, N. N, Veluchamy, Devi, H. N, Lakshmikanthan, Sridevi, & Akila, B. (2024). Urolithiasis treated by siddha Medicine: A case report. World Journal of Pharmaceutical Science and Research, 3(2), 285–293. https://doi.org/10.5281/zenodo.11142334DOIGOOGLE SCHOLAR
    59. Rajalakshmi, P, Vadivel, V, & Brindha, P. (2017). Investigation of in vitro antioxidant and anti-inflammatory activities of selected siddha polyherbal formulations. Indian J Pharm Educ Res. 51(4 Suppl):s747–, 53. https://doi.org/10.5530/ijper.51.4DOIGOOGLE SCHOLAR
    60. Rajamohamed, B. (2019). S; Siddharthan, S. Modulatory Effects of Amukkara Choornam on Candida Albicans Biofilm: in Vitro and in Vivo Study. Molecular Biology Reports, 46(3), 2961–2969. https://doi.org/10.1007/s11033-019-04757-zDOIGOOGLE SCHOLAR
    61. Rakshitaa, S, Vadivel, V, & Brindha, P. (2015). Evaluation of Physico-Chemical and antioxidant properties of an indian siddha Formulation: Panchadeepakini choornam. Int. J. Pharm. Sci. Rev. Res, 35(1), 67–73.GOOGLE SCHOLAR
    62. Ramkumar, G. (2014). G; Parthibhan, P; Thanigavelan, V; Kaliyamurthi, V. Acute and 28 Days Repeated Oral Toxicity Studies of a Siddha Drug Kalamega Narayana Chendooram in Kodiveli Verpattai Chooranam on Wistar Albino Rats. International Journal of Pharmaceutical and Biological Archives, 5(3), 46–51.GOOGLE SCHOLAR
    63. Ravichandran, M. (2014). Cardio protective activity of venthamarai chooranam - A siddha preparation. Available From: Cardio Protective Activity of Venthamarai Chooranam - a Siddha Preparation.GOOGLE SCHOLAR
    64. Revathy, P. (2019). Antihyperglycemic effect of komoothira silasathu parpam in streptozotocin induced diabetic rats. Journal of Research in Biomedical Sciences, 1(3), 1–7.GOOGLE SCHOLAR
    65. Satheesh, G, Balasubramanian, S, Kalaiselvi, d, & Abinaya, R. (2024). Kaalamega narayana chendhooram (KMNC): Standardization, Characterization, and instrumental analysis of a potential Anti- Oral, Anti-Lung, and Anti-Prostate cancer of herbal mineral formulation (A siddha medicine for Oral, Lung, and prostate cancer). Future J. Pharm Health. Sci, 3(3), 314–331. https://doi.org/10.26452/fjphs.v3i3.487DOIGOOGLE SCHOLAR
    66. Shalini, B. K. (2025). Suresh; meenakshi Sundaram, M. Siddha System of Medicine: a Review of Basic Concepts and Evidence-based Herbal Remedies for Respiratory Diseases. Journal of Population Therapeutics and Clinical Pharmacology, 32(5), 983–992. https://doi.org/10.53555/8dvqyf54DOIGOOGLE SCHOLAR
    67. Shanmugapriya, P, Gayatri, R, Varshini, K, Subathra, T, Murugan, & Ramamurthy (2025). Management of maxillary polyposis through siddha - A case report. Bioinformation, 21(9), 3374–3380. https://doi.org/10.6026/973206300213374DOIGOOGLE SCHOLAR
    68. Sharma, M, Gaidhane, A, & Choudhari, S. (2024). G. A Comprehensive Review on Trends and Patterns of Non-communicable Disease Risk Factors in India. Cureus, 16(3), e57027. https://doi.org/10.7759/cureus.57027DOIGOOGLE SCHOLAR
    69. Singh, A, Shukla, A, Ram, F, & Kumar, K. (2017). Trends in inequality in length of life in India: A decomposition analysis by age and causes of death. Genus, 73(1), 5. https://doi.org/10.1186/s41118-017-0022-6DOIGOOGLE SCHOLAR
    70. Singh, S. (2024). K. C. M. Siddha Medicine for Cardiovascular Disease Prevention and Management: a Comprehensive Review. European Journal of Cardiovascular Medicine, 14, 899–902.GOOGLE SCHOLAR
    71. Sivamanisha, V, Suresh, K, & Sundaram, M. (2022). M; Meenakumari, R. An Immunomodulatory Activity of Siddha Formulation Seenthil Chooranam By in Vitro Study V. Int J Trans Res Ind Med, 4(3), 35–39.GOOGLE SCHOLAR
    72. Sivaranjani, K, & Santhoshkumar (2025). A review on therapeutic effect of siddha classical formulation seenthil chooranam. Journal of Drug Delivery and Therapeutics, 15(3), 151–160. https://doi.org/10.22270/jddt.v15i3.7024DOIGOOGLE SCHOLAR
    73. (STG), & S. T. G. O. M. O. M. D. I, S. S. O. M. (2025). Ayush vertical. New Delhi.: Directorate General of Health Services.GOOGLE SCHOLAR
    74. (STG), S. S. T. G. (2019). National institute of Siddha, ministry of Ayush, govt of india.GOOGLE SCHOLAR
    75. Tamilselvan, R, Bharathi, K, & Semalatha, S. (2022). Anti-Hypertensive activity of siddha Herbo-Mineral formulation eladhi chooranam in spontaneously hypertensive rats. European Journal Pharmaceutical and Medical Research, 9(6), 218–222.GOOGLE SCHOLAR
    76. Thanigavelan, V, Rajamanickam, V, G, Kaliyamurthi, V, Lakshmanakumar, V, Sasikala, N, Thirunavukkarasu, S, & V (2011). Antibacterial and hemostatic activities of A siddha Formulation-. Pavala Parpam. Pharmacologyonline, 1, 613–624.GOOGLE SCHOLAR
    77. Thanuja, N. (2021). K; Azamthulla, Mohammad; Sandhya, K. V. a Potential Siddha Mineral Drug; Pavala Parpam. International Journal of Current Pharmaceutical Research, 5(4), 306–312.GOOGLE SCHOLAR
    78. Thirupathi, A. (2002). T; Venkatanarayanan, R; Hemalatha, R. Pharmacological Validation of Two Siddha Drugs (parpams) for Antiulcer Effect in Albinorats: a Preliminary Study. Ancient Science of Life, 22(1), 48–54.GOOGLE SCHOLAR
    79. Vaishnavi, A. V, Rashika, R, Rangasamy, S, T, & Thiyagasundaram (2024). Evaluation of in vitro cytotoxicity activity of poorna Chandhordhayam-(A siddha nano golddrug) against mda Mb231 breast cancer cell line using mtt assay. Afr. J. Biomed. Res, 27(3S), 250–257. https://doi.org/10.53555/AJBR.v27i3S.1937DOIGOOGLE SCHOLAR
    80. Vanitha, A, Praveena, R, Seethalakshmi, G, Sundaram, M, M, & Muthukumar, N. (2020). J. In Vitro Antioxidant Property of a Siddha Drug Kasthuri Mathirai. World Journal of Pharmaceutical Research, 9(1), 1590–1595. https://doi.org/10.20959/wjpr20201-16543DOIGOOGLE SCHOLAR
    81. Varghese, C, Prem, A, Nongkynrih, B, Chattu, V. K, Mikkelsen, diseases, & B, F. U. O. N. (2025). An opportunity to bridge the transcending priorities for impact in global south. PLOS Global Public Health, 5(3), e0004287. https://doi.org/10.1371/journal.pgph.0004287DOIGOOGLE SCHOLAR
    82. Velmurugana, V, Subab, V, & Manickavasakamc, K. (2013). Sub-Acute toxicity study of parangipattai rasayanam. Int J Pharm Bio Sci, 3(4), 182–187.GOOGLE SCHOLAR
    83. Vikesh, B, Radha, S, Thanikaiselvi, S, & Thiruthani, M. (2018). Acute and chronic toxicity study of silasathu parpam on wister albino rats. Int. J. Curr. Res. Biol. Med, 3(5), 6–13. https://doi.org/10.22192/ijcrbm.2018.03.05.002DOIGOOGLE SCHOLAR
    84. Vimala, J, M, Jeylani, A. K, & MP (2022). Muthu Parpam- Heavy metal analysis by ICP-OES. Journal of Traditional and Integrative Medicine, 5(2), 473–476.GOOGLE SCHOLAR
    85. Vinubharathi, B, & Muthukumar, N. (2018). J; Mahalakshmi, V; Banumathi, V. In Vitro Antidiabetic Activity of Siddha Polyhedral Drug Maruthampattai Kudineer. World Journal of Pharmaceutical Research, 7(16), 1359–1364. https://doi.org/10.20959/wjpr201816-13250DOIGOOGLE SCHOLAR
    86. Vinubharathi, B, Mahalakshmi, V, & Muthukumar, N. (2019). J; Suresh, R; Banumathi, V. Screening of in Vitro Antioxidant Activity of Methanolic Extract of Maruthampattai Kudineer-a Siddha Polyherbal Preparation. Research Journal of Pharmacy and Technology, 12(1), 219–222. https://doi.org/10.5958/0974-360X.2019.00040.4DOIGOOGLE SCHOLAR
    87. Vinubharathi, b, Mahalakshmi, v, Muthukumar, & j, N. (2019). Ninety days repeated dose oral toxicity study of maruthampattai kudineer in wistar rats. Int. J. Curr. Res. Med. Sci, 5(6), 23–3. https://doi.org/10.22192/ijcrms.2019.05.06.003DOIGOOGLE SCHOLAR

    Cite this article

    SELECT FORMAT

    Raja, N. N. J., & Veluchamy, H. N. D. (2026). Siddha Medicine in Cardiovascular Care: Clinical Evidence and Pharmacological Perspectives for Integrative Management-An Integrative Review. Pharmacognosy Research, 18(4), 1150–1158. https://doi.org/10.5530/pres.20260030